Thymosin in cancer patients: In vitro effects and correlations with clinical response to thymosin immunotherapy

P. B. Chretien, S. D. Lipson, R. Makuch, D. E. Kenady, M. H. Cohen, J. D. Minna

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Studies on the effect of thymosin on T-cell levels in vitro among normal persons and cancer patients show that, in general, T-cell levels increase after incubation with thymosin in populations with low initial T-cell levels while the levels decrease in populations with high initial T-cell levels. In patients with small cell carcinoma of the lung receiving intensive chemotherapy also randomized to receive thymosin at a dose of 60 mg/m 2, thymosin at a dose of 20 mg/m 2, or placebo twice weekly, increased survival occurred in patients receiving the thymosin dose of 60 mg/m 2. The increase in survival was greatest in patients with low pretreatment T-cell and α 2HS-glycoprotein levels. These observations suggest that the cancer patients most likely to benefit therapeutically from adjuvant treatment with thymosin are those with relatively low initial T-cell levels and other parameters of cellular immunity.

Original languageEnglish (US)
Pages (from-to)1787-1790
Number of pages4
JournalCancer Treatment Reports
Volume62
Issue number11
StatePublished - 1978

Fingerprint

Thymosin
Immunotherapy
T-Lymphocytes
Neoplasms
Survival
Small Cell Lung Carcinoma
Population Dynamics
Cellular Immunity
In Vitro Techniques
Glycoproteins
Placebos
Drug Therapy
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chretien, P. B., Lipson, S. D., Makuch, R., Kenady, D. E., Cohen, M. H., & Minna, J. D. (1978). Thymosin in cancer patients: In vitro effects and correlations with clinical response to thymosin immunotherapy. Cancer Treatment Reports, 62(11), 1787-1790.

Thymosin in cancer patients : In vitro effects and correlations with clinical response to thymosin immunotherapy. / Chretien, P. B.; Lipson, S. D.; Makuch, R.; Kenady, D. E.; Cohen, M. H.; Minna, J. D.

In: Cancer Treatment Reports, Vol. 62, No. 11, 1978, p. 1787-1790.

Research output: Contribution to journalArticle

Chretien, PB, Lipson, SD, Makuch, R, Kenady, DE, Cohen, MH & Minna, JD 1978, 'Thymosin in cancer patients: In vitro effects and correlations with clinical response to thymosin immunotherapy', Cancer Treatment Reports, vol. 62, no. 11, pp. 1787-1790.
Chretien, P. B. ; Lipson, S. D. ; Makuch, R. ; Kenady, D. E. ; Cohen, M. H. ; Minna, J. D. / Thymosin in cancer patients : In vitro effects and correlations with clinical response to thymosin immunotherapy. In: Cancer Treatment Reports. 1978 ; Vol. 62, No. 11. pp. 1787-1790.
@article{5b7aad5e461f4f479e6d72f01f96318a,
title = "Thymosin in cancer patients: In vitro effects and correlations with clinical response to thymosin immunotherapy",
abstract = "Studies on the effect of thymosin on T-cell levels in vitro among normal persons and cancer patients show that, in general, T-cell levels increase after incubation with thymosin in populations with low initial T-cell levels while the levels decrease in populations with high initial T-cell levels. In patients with small cell carcinoma of the lung receiving intensive chemotherapy also randomized to receive thymosin at a dose of 60 mg/m 2, thymosin at a dose of 20 mg/m 2, or placebo twice weekly, increased survival occurred in patients receiving the thymosin dose of 60 mg/m 2. The increase in survival was greatest in patients with low pretreatment T-cell and α 2HS-glycoprotein levels. These observations suggest that the cancer patients most likely to benefit therapeutically from adjuvant treatment with thymosin are those with relatively low initial T-cell levels and other parameters of cellular immunity.",
author = "Chretien, {P. B.} and Lipson, {S. D.} and R. Makuch and Kenady, {D. E.} and Cohen, {M. H.} and Minna, {J. D.}",
year = "1978",
language = "English (US)",
volume = "62",
pages = "1787--1790",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Thymosin in cancer patients

T2 - In vitro effects and correlations with clinical response to thymosin immunotherapy

AU - Chretien, P. B.

AU - Lipson, S. D.

AU - Makuch, R.

AU - Kenady, D. E.

AU - Cohen, M. H.

AU - Minna, J. D.

PY - 1978

Y1 - 1978

N2 - Studies on the effect of thymosin on T-cell levels in vitro among normal persons and cancer patients show that, in general, T-cell levels increase after incubation with thymosin in populations with low initial T-cell levels while the levels decrease in populations with high initial T-cell levels. In patients with small cell carcinoma of the lung receiving intensive chemotherapy also randomized to receive thymosin at a dose of 60 mg/m 2, thymosin at a dose of 20 mg/m 2, or placebo twice weekly, increased survival occurred in patients receiving the thymosin dose of 60 mg/m 2. The increase in survival was greatest in patients with low pretreatment T-cell and α 2HS-glycoprotein levels. These observations suggest that the cancer patients most likely to benefit therapeutically from adjuvant treatment with thymosin are those with relatively low initial T-cell levels and other parameters of cellular immunity.

AB - Studies on the effect of thymosin on T-cell levels in vitro among normal persons and cancer patients show that, in general, T-cell levels increase after incubation with thymosin in populations with low initial T-cell levels while the levels decrease in populations with high initial T-cell levels. In patients with small cell carcinoma of the lung receiving intensive chemotherapy also randomized to receive thymosin at a dose of 60 mg/m 2, thymosin at a dose of 20 mg/m 2, or placebo twice weekly, increased survival occurred in patients receiving the thymosin dose of 60 mg/m 2. The increase in survival was greatest in patients with low pretreatment T-cell and α 2HS-glycoprotein levels. These observations suggest that the cancer patients most likely to benefit therapeutically from adjuvant treatment with thymosin are those with relatively low initial T-cell levels and other parameters of cellular immunity.

UR - http://www.scopus.com/inward/record.url?scp=0018249615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018249615&partnerID=8YFLogxK

M3 - Article

C2 - 215307

AN - SCOPUS:0018249615

VL - 62

SP - 1787

EP - 1790

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 11

ER -